The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the ...
CEO Tassos Gianakakos said having late-stage assets and a team fortified at MyoKardia really resonated with investors. SpaceX ...
In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...
At this point in product development, acceleration is a natural urge. But while it’s tempting to prioritize speed, it’s ...
Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic ...
Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an ...
One of the year’s largest venture funding rounds comes just after a head-to-head study showed Ollin’s drug — licensed from a ...
AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent ...
The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are ...
The endorsement of an advisory committee positions Moderna to complete a dramatic turnaround for a shot the FDA declined to ...
Some analysts argue that, even for competitors, a big clinical trial win for Definium Therapeutics helps validate the ...
The agency took another step toward clearing a backlog of Makary-era rejections that appeared to contradict earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results